{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:03:34Z","timestamp":1794330214295,"version":"4.9.0"},"reference-count":29,"publisher":"BMJ","issue":"19","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/19\/64\/34434"],"award-info":[{"award-number":["PG\/19\/64\/34434"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2025,3,19]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer agents, but are associated with cancer therapy-related cardiac dysfunction (CTRCD) and hypertension. The timing, frequency and magnitude of these toxicities are poorly defined. The objective of this study is therefore to investigate the incidence, time course and mechanisms of VEGFI-associated CTRCD and hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients commencing VEGFI underwent blood pressure (BP) monitoring, echocardiography and cardiac biomarker measurement at baseline and prospectively over 24 weeks. Serial adenosine stress perfusion cardiovascular MRI (CMR) was performed in a substudy. CTRCD was defined as left ventricular ejection fraction (LVEF) decline by \u226510\u2009percentage points from baseline to a value &lt;50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>78 patients participated (68% men; age 63\u00b111 years). 15 patients (19%) developed CTRCD, and it was evident at 4 weeks in 93% of cases. Overall, LVEF was 4.2% (95% CI: \u22126.2% to \u22122.3%, p&lt;0.001) lower than baseline at 4 weeks. At 4 weeks, N-terminal pro-brain natriuretic peptide, but not troponin, was higher in patients with CTRCD. 62 (77%) patients developed hypertension. Home systolic and diastolic BP increased by 7.2\u2009mm Hg (4.7\u20139.8, p&lt;0.001) and 4.8\u2009mm Hg (3.1\u20136.5, p&lt;0.001), respectively, at 1\u2009week. There was no association between change in LVEF and BP.<\/jats:p>\n                    <jats:p>CMR-derived LVEF, T1 relaxation times and resting myocardial blood flow (n=46) were 5.2% (\u22127.3% to \u22123.1%, p&lt;0.001), 27 ms (\u221240 to \u221214, p&lt;0.001) and 14.7 mL\/100mL\/min (\u221224.2 to \u22125.1, p=0.004), respectively, lower at 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>VEGFI-associated CTRCD is frequent and occurs early. This finding has implications for prioritising early cardiac imaging follow-up after commencing treatment. Underlying mechanisms include myocardial and microvascular effects that are at least partly independent of hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/heartjnl-2024-325535","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T18:50:29Z","timestamp":1743706229000},"page":"925-932","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging"],"prefix":"10.1136","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-0242","authenticated-orcid":false,"given":"Stephen J H","family":"Dobbin","sequence":"first","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3505-7440","authenticated-orcid":false,"given":"Kenneth","family":"Mangion","sequence":"additional","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-8636","authenticated-orcid":false,"given":"Colin","family":"Berry","sequence":"additional","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"},{"name":"Cardiology, Golden Jubilee National Hospital, Clydebank, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Roditi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Glasgow Royal Infirmary, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita","family":"Basak","sequence":"additional","affiliation":[{"name":"UK Research and Innovation, Didcot, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"McClure","sequence":"additional","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriona","family":"Brooksbank","sequence":"additional","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Sonecki","sequence":"additional","affiliation":[{"name":"Queen Elizabeth University Hospital, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sourbron","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield\u2014Western Bank Campus, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Evans","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"White","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-3643","authenticated-orcid":false,"given":"Paul","family":"Welsh","sequence":"additional","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Butler","sequence":"additional","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Venugopal","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian M","family":"Touyz","sequence":"additional","affiliation":[{"name":"Research Institute of McGill University Health Centre, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Jones","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian N","family":"Lang","sequence":"additional","affiliation":[{"name":"University of Glasgow BHF Glasgow Cardiovascular Research Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"2025092005354828000_111.19.925.1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaccao.2023.12.010","article-title":"Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials","volume":"6","author":"Rankin","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2025092005354828000_111.19.925.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2012.09.001"},{"key":"2025092005354828000_111.19.925.3","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ejhf.1847","article-title":"Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer","volume":"22","author":"Dobbin","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025092005354828000_111.19.925.4","doi-asserted-by":"publisher","DOI":"10.1530\/ERP-20-0026"},{"key":"2025092005354828000_111.19.925.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"2025092005354828000_111.19.925.6","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"key":"2025092005354828000_111.19.925.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"2025092005354828000_111.19.925.8","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"2025092005354828000_111.19.925.9","unstructured":"National Institute of Health . National cancer institute common terminology criteria for adverse events (CTCAE) version 5.0. NIH Publ; 2017."},{"key":"2025092005354828000_111.19.925.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"2025092005354828000_111.19.925.11","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920"},{"key":"2025092005354828000_111.19.925.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.12.008"},{"key":"2025092005354828000_111.19.925.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2869"},{"key":"2025092005354828000_111.19.925.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.073"},{"key":"2025092005354828000_111.19.925.15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025092005354828000_111.19.925.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2015.11.005"},{"key":"2025092005354828000_111.19.925.17","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-14-27"},{"key":"2025092005354828000_111.19.925.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61865-0"},{"key":"2025092005354828000_111.19.925.19","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfn157"},{"key":"2025092005354828000_111.19.925.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2008.00090.x"},{"key":"2025092005354828000_111.19.925.21","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-15-92"},{"key":"2025092005354828000_111.19.925.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5050"},{"key":"2025092005354828000_111.19.925.23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp417"},{"key":"2025092005354828000_111.19.925.24","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08111109"},{"key":"2025092005354828000_111.19.925.25","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine Kinase Inhibitor-Induced Hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2025092005354828000_111.19.925.26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/HYPERTENSIONAHA.120.16454","article-title":"Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial","volume":"77","author":"M\u00e4ki-Pet\u00e4j\u00e4","year":"2021","journal-title":"Hypertension"},{"key":"2025092005354828000_111.19.925.27","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients","volume":"128","author":"van Dorst","year":"2021","journal-title":"Circ Res"},{"key":"2025092005354828000_111.19.925.28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025092005354828000_111.19.925.29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp025"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2024-325535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T12:35:53Z","timestamp":1758371753000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2024-325535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":29,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,9,11]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/heartjnl-2024-325535"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2024-325535","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}